专利检索 ap:("AMGEN INC.") AND inv:"Brian Alan Lanman" 第 1 页

1.

发明授权
Apelin polypeptides 有权

公开(公告)号：US11807693B2

公开(公告)日：2023-11-07

申请号：US17160819

申请日：2021-01-28

申请人： AMGEN INC.

发明人： Jerry Ryan Holder , Gayathri Swaminath , Michael J. Frohn , Brian Alan Lanman , Anthony B. Reed , Leslie P. Miranda , John Gordon Allen , Alexander J. Pickrell , Aaron C. Siegmund , Lewis D. Pennington , Bryant Yang

IPC分类号： C07K7/08 , C07K14/47 , A61K47/54 , A61K47/60 , A61K38/10 , A61K38/00

CPC分类号： C07K7/08 , A61K38/10 , A61K47/542 , A61K47/60 , C07K14/47 , A61K38/00 , C07K2319/30

摘要： The invention provides modified apelin polypeptides having increased stability, circulating half-life, and/or potency relative to the native apelin-13 polypeptide. Compositions comprising the modified apelin polypeptides and methods of using the polypeptides for treating cardiac disorders, such as heart failure, are also disclosed.

2.

发明授权
KRAS G12C inhibitors and methods of using the same 有权

公开(公告)号：US11096939B2

公开(公告)日：2021-08-24

申请号：US16428163

申请日：2019-05-31

申请人： Amgen Inc.

发明人： Shon Booker , John Gordon Allen , Brian Alan Lanman , Ryan Paul Wurz , Ning Chen , Victor J. Cee , Patricia Lopez , Aaron C. Siegmund , Michael D. Bartberger

IPC分类号： C07D471/04 , A61K31/497 , C07K16/28

摘要： Provided herein are KRAS G12C inhibitors, such as composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.

3.

发明授权
Apelin polypeptides 有权

公开(公告)号：US10941182B2

公开(公告)日：2021-03-09

申请号：US15317911

申请日：2015-06-10

申请人： AMGEN INC.

发明人： Jerry Ryan Holder , Gayathri Swaminath , Michael J. Frohn , Brian Alan Lanman , Anthony B. Reed , Leslie P. Miranda , John G. Allen , Alexander J. Pickrell , Aaron C. Siegmund , Lewis D. Pennington , Bryant Yang

IPC分类号： C07K7/08 , A61K38/10 , C07K14/47 , A61K47/54 , A61K47/60 , A61K38/00

摘要： The invention provides modified apelin polypeptides having increased stability, circulating half-life, and/or potency relative to the native apelin-13 polypeptide. Compositions comprising the modified apelin polypeptides and methods of using the polypeptides for treating cardiac disorders, such as heart failure, are also disclosed.

4.

发明授权
KRAS G12C inhibitors and methods of using the same 有权

公开(公告)号：US11905281B2

公开(公告)日：2024-02-20

申请号：US17031607

申请日：2020-09-24

申请人： Amgen Inc.

发明人： Brian Alan Lanman , Jian Chen , Anthony B. Reed , Victor J. Cee , Longbin Liu , David John Kopecky , Patricia Lopez , Ryan Paul Wurz , Thomas T. Nguyen , Shon Booker , Nobuko Nishimura , Youngsook Shin , Nuria A. Tamayo , John Gordon Allen , Jennifer Rebecca Allen

IPC分类号： C07D471/04 , C07D213/82 , C07D417/04 , A61K38/07 , C07D487/08 , C07D417/12 , C07D513/04 , C07D487/10 , C07D487/04 , C07D401/04 , C07D239/80 , C07D401/14 , C07D237/34 , C07D403/04 , A61K31/496 , A61K31/416 , A61K31/55 , A61K31/454 , A61K31/519 , A61K31/502 , A61K31/517 , A61K31/5025 , A61P35/00 , A61K31/7068 , C07D275/04 , C07D475/00

CPC分类号： C07D417/04 , A61K31/416 , A61K31/454 , A61K31/496 , A61K31/502 , A61K31/5025 , A61K31/517 , A61K31/519 , A61K31/55 , A61K31/7068 , A61K38/07 , A61P35/00 , C07D237/34 , C07D239/80 , C07D275/04 , C07D401/04 , C07D401/14 , C07D403/04 , C07D417/12 , C07D471/04 , C07D475/00 , C07D487/04 , C07D487/08 , C07D487/10 , C07D513/04

摘要： Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.

5.

发明授权
PRMT5 inhibitors 有权

公开(公告)号：US11845760B2

公开(公告)日：2023-12-19

申请号：US17552016

申请日：2021-12-15

申请人： AMGEN INC.

发明人： Shon Booker , Matthew Paul Bourbeau , John R. Butler , Sanne Ormholt Schroder Glad , Brian Alan Lanman , Patricia Lopez , Francesco Manoni , Liping H. Pettus , Ian Sarvary , Nuria A. Tamayo , Mikkel Vestergaard , Nicholas Anthony Weires

IPC分类号： C07D471/04 , C07D471/14 , C07D491/04 , C07D491/14 , C07D495/04 , A61K31/4355 , A61K31/436 , A61K31/4365 , A61K31/437 , A61K31/4375 , A61P35/00 , C07D491/06 , C07D471/06 , C07D471/16 , C07D491/16

CPC分类号： C07D491/06 , A61P35/00 , C07D471/06 , C07D471/16 , C07D491/16

摘要： Described herein are novel PRMT5 inhibitors of Formula I and pharmaceutically acceptable salts thereof, as well as the pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity and may have use in treating proliferative, metabolic and blood disorders. Compounds of Formula I have the following structure:

6.

发明授权
KRAS G12C inhibitors and methods of using the same 有权

公开(公告)号：US11045484B2

公开(公告)日：2021-06-29

申请号：US16402589

申请日：2019-05-03

申请人： Amgen Inc.

发明人： Ryan Paul Wurz , Victor J. Cee , Albert Amegadzie , Ning Chen , Brian Alan Lanman , Michael D. Bartberger

IPC分类号： A61K31/675 , A61P35/00 , A61K31/167 , A61K31/553 , C07K16/30 , A61K45/06

摘要： Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.

7.

发明申请
COMPOUNDS THAT INHIBIT MCL-1 PROTEIN 审中-公开

公开(公告)号：US20180289720A1

公开(公告)日：2018-10-11

申请号：US15938001

申请日：2018-03-28

申请人： AMGEN INC.

发明人： Paul E. Harrington , Kate Ashton , Sean P. Brown , Matthew R. Kaller , Todd J. Kohn , Brian Alan Lanman , Kexue Li , Yunxiao Li , Jonathan D. Low , Ana Elena Minatti , Alexander J. Pickrell , Markian M. Stec , Joshua Taygerly

IPC分类号： A61K31/553 , A61P35/00

CPC分类号： A61K31/553 , A61P35/00 , A61P35/02 , C07D498/08

摘要： Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

8.

发明授权
Inhibitors of PI3 kinase and/or mTOR 有权
标题翻译： PI3激酶抑制剂和/或mTOR

公开(公告)号：US08772480B2

公开(公告)日：2014-07-08

申请号：US13681230

申请日：2012-11-19

申请人： Amgen Inc.

发明人： Kristin L. Andrews , Yunxin Y. Bo , Shon Booker , Victor J. Cee , Noel D'Angelo , Bradley J. Herberich , Fang-Tsao Hong , Claire L. M. Jackson , Brian Alan Lanman , Hongyu Liao , Longbin Liu , Nobuko Nishimura , Mark H. Norman , Liping H. Pettus , Anthony B. Reed , Adrian Leonard Smith , Seifu Tadesse , Nuria A. Tamayo , Bin Wu , Ryan Wurz , Kevin C. Yang

IPC分类号： C07D401/04 , C07D401/14 , A61K31/444 , A61K31/53 , A61P35/00

CPC分类号： C07D473/00 , C07D401/14 , C07D405/14 , C07D413/14 , C07D417/14

摘要： The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt thereof; methods of treating diseases or conditions, such as cancer, using the compounds; and pharmaceutical compositions containing the compounds, wherein the variables are as defined herein.

摘要翻译： 本发明涉及式I化合物或其药学上可接受的盐; 使用该化合物治疗疾病或病症如癌症的方法; 和含有这些化合物的药物组合物，其中变量如本文所定义。